Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.53 |
| ▸ | KLK7 | P49862 | 2/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.51 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8177426 | 1.00 | PPARA (0.58) | PPARAACEPPARGCTSKKLK7 | |
| SCHEMBL376018 | 0.93 | PPARA (0.61) | PPARAACEPPARGCTSKKLK7 | |
| SCHEMBL428113 | 0.93 | PPARA (0.61) | PPARAACEPPARGCTSKKLK7 | |
| SCHEMBL2009896 | 0.93 | PPARA (0.61) | PPARAACEPPARGCTSKKLK7 | |
| SCHEMBL8322873 | 0.92 | KLK5 (0.53) | PPARAACECTSKKLK7KLK5 | |
| SCHEMBL8113270 | 0.91 | SIRT2 (0.55) | PPARAACEPPARGCTSKCTSS | |
| SCHEMBL6806283 | 0.89 | ITGB3 (0.49) | PPARAACEPPARGCTSKKLK7 | |
| SCHEMBL22404783 | 0.89 | CTSK (0.49) | PPARAACECTSKKLK7KLK5 | |
| SCHEMBL25985265 | 0.89 | CTSK (0.49) | PPARAACEPPARGCTSKKLK7 | |
| SCHEMBL13702217 | 0.89 | PPARA (0.56) | PPARAACEPPARGCTSKKLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3935042-B1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC (KR) | 2024-08-28 | — | — | EP | disclosed |
| US-12071412-B2 | Caspase inhibitors and methods of use thereof | NOBO MEDICINE INC. (KR) | 2024-08-27 | — | — | US | disclosed |
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2023-08-10 | — | — | US | disclosed |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | HISTOGEN, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20200283396-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2020-09-10 | — | — | US | disclosed |
| US-6110933-A | AN ENZYME INHIBITOR TREATING PANCREATITIS, HEPATITIS, CHRONIC RENAL FAILURE, ENDOTOXIN SHOCK, GRAM-NEGATIVE SEPTIC SHOCK, ARTHRITIS, RESPIRATORY DISEASE, HEART DISEASE, ALLERGIC DISEASE, THROMBOSIS, ARTERIOSCLEROSIS, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-0741697-B1 | AMINO ACID DERIVATIVES AND THEIR USE AS PHOSPHOLIPASE A2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-09-15 | — | — | EP | disclosed |
| EP-0741697-A1 | AMINO ACID DERIVATIVES AND THEIR USE AS PHOSPHOLIPASE A2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995019959-A1 | AMINO ACID DERIVATIVES AND THEIR USE AS PHOSPHOLIPASE A2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP1, CASP3, CASP7 | PPARA 3631/4885ACE 297/4885PPARG 3105/4885 |
| US-20200283396-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP1, CASP3, CASP7 | PPARA 3631/4885ACE 297/4885PPARG 3105/4885 |
| US-12071412-B2 | Caspase inhibitors and methods of use thereof | CASP1, CASP3, CASP7 | PPARA 3631/4885ACE 297/4885PPARG 3105/4885 |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | CASP1, CASP3, CASP7 | PPARA 3631/4885ACE 297/4885PPARG 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.